Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
NCT ID: NCT00030966
Last Updated: 2009-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1200 participants
INTERVENTIONAL
2002-01-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
NCT00027300
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00097760
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
NCT00168766
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
NCT00559702
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
NCT01405820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
Natalizumab
Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
Group 2
Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.
Placebo
Placebo monthly infusion for up to 116 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Natalizumab
Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
Placebo
Placebo monthly infusion for up to 116 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between the ages of 18 and 55, inclusive
* Baseline EDSS score between 0.0 and 5.0, inclusive
* Have been treated with Avonex for at least the 12 months prior to randomization
* Have experienced at least one relapse (while on Avonex) within the 12 months prior to randomization.
* Cranial MRI scan demonstrating lesions consistent with MS.
* Have given written informed consent to participate in the study.
Exclusion Criteria
* MS relapse has occurred within 50 days of randomization
* A clinically significant infectious illness within 30 days prior to randomization
* History of, or abnormal lab result, indicative of significant disease, that in the opinion of the investigator, would preclude the administration of a recombinant humanized antibody immunomodulating agent or Avonex for 116 weeks.
* History of severe allergic or anaphylactic reactions or known drug hypersensitivity.
* Unable to perform the Timed 25-Foot Walk, 9HPT and PASAT 3
* Abnormal blood tests at Screening Visit
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Elan Pharmaceuticals
INDUSTRY
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Biogen Idec
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Panzara, MD, MPH
Role: STUDY_DIRECTOR
Biogen
Richard A Rudick, MD
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama-Birmingham, Department of Neurology
Birmingham, Alabama, United States
Phoenix Neurological Associates, Ltd.
Phoenix, Arizona, United States
University of Arkansas For Medical Sciences
Little Rock, Arkansas, United States
University of California - Irvine
Irvine, California, United States
USC MS Comprehensive Care Center
Los Angeles, California, United States
Kaiser-Permanente Medical Center
Redwood City, California, United States
MS Center at UCSF
San Francisco, California, United States
Healthsouth Rehabilitation Hospital
Colorado Springs, Colorado, United States
University of Colorado MS Center
Denver, Colorado, United States
Griffin Hospital
Derby, Connecticut, United States
Georgetown Univesity Hospital, Research Pharmacy
Washington D.C., District of Columbia, United States
George Washington University MS Center
Washington D.C., District of Columbia, United States
North Ridge NeuroScience Center
Fort Lauderdale, Florida, United States
Maitland Neurology
Maitland, Florida, United States
University of Miami, Department of Neurology
Miami, Florida, United States
The Multiple Sclerosis Center of Atlanta
Atlanta, Georgia, United States
Marietta Neurological Associates
Marietta, Georgia, United States
Northwestern University, Department of Neurology
Chicago, Illinois, United States
Rush-Presbyterian St. Luke's Medical Center
Chicago, Illinois, United States
Alexian Brothers Center for Clinical Research
Elk Grove Village, Illinois, United States
Loyola Medical Center
Maywood, Illinois, United States
Consultants in Neurology Northbrook
Northbrook, Illinois, United States
Springfield Clinic Neuroscience Institute
Springfield, Illinois, United States
Indiana University Medical Center
Indianapolis, Indiana, United States
Mercy Hospital Outpatient Pharmacy
Des Moines, Iowa, United States
LSU Neurolgoy Clinic in New Orleans
New Orleans, Louisiana, United States
Maine Neurology
Scarborough, Maine, United States
University of Maryland Hospital, Department of Neurology
Baltimore, Maryland, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
Michigan State University MS Clinic
East Lansing, Michigan, United States
Michigan Institute for Neurological Disorders
Farmington Hills, Michigan, United States
Noran Neurological Clinic
Minneapolis, Minnesota, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
St. John's Mercy Medical Center
St Louis, Missouri, United States
Bernard W. Gimbel MS Center
Teaneck, New Jersey, United States
Upstate Clinical Research, LLC
Albany, New York, United States
Albany Medical Center
Albany, New York, United States
Maimonides Medical Center, Division of Neurology
Brooklyn, New York, United States
Buffalo General Hospital, Department of Neurology
Buffalo, New York, United States
MS Care Center
New York, New York, United States
St. Luke's Roosevelt Hospital, MS Research & Treatment Center
New York, New York, United States
New York Hospital - Cornell Medical Center
New York, New York, United States
New York State Psychiatric Institution
New York, New York, United States
Strong Health Pharmacy Services
Rochester, New York, United States
Staten Island University Hospital
Staten Island, New York, United States
University Hospital at Stony Brook
Stony Brook, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
MS Center at Carolinas Medical Center
Charlotte, North Carolina, United States
Raleigh Neurology Associates
Raleigh, North Carolina, United States
Wake Forest University School of Medicine, Department of Neurology
Winston-Salem, North Carolina, United States
Riverhills Neurology
Cincinnati, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Providence Saint Vincent Medical Center
Portland, Oregon, United States
Geisinger Medical Center
Danville, Pennsylvania, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Greenstein Neurology Associates & MS Institute
Philadelphia, Pennsylvania, United States
Allegheny Singer Research Institute
Pittsburgh, Pennsylvania, United States
University of Pittsburgh, Department of Neurology
Pittsburgh, Pennsylvania, United States
University of Tennessee - Memphis
Memphis, Tennessee, United States
Vanderbilt Medical Center
Nashville, Tennessee, United States
Option Care Infusion
Dallas, Texas, United States
UTSW Medical School
Dallas, Texas, United States
Baylor Methodist International MS Center
Houston, Texas, United States
Central Texas Neurology
Round Rock, Texas, United States
Fletcher Allen Health Care
Burlington, Vermont, United States
University of Virginia Health Sciences
Charlottesville, Virginia, United States
Neurological Associates, Inc.
Richmond, Virginia, United States
Virginia Mason Medical Center
Seattle, Washington, United States
MS Research Center
Seattle, Washington, United States
St. Francis Hospital, Center for Neurological Disorders
Milwaukee, Wisconsin, United States
Universitatsklinik fur Neurologie
Graz, , Austria
Universitatsklinik fur Neurologie
Innsbruck, , Austria
Hopital Universitaire U.L.B. Erasme
Brussels, , Belgium
Elisabeth Ziekenhuis
Sijsele, , Belgium
Hopital Pellegrin Tripode, Neurologie
Bordeaux, , France
Hopital neurologique Pierre Werth
Lyon, , France
Judisches Krankenhaus
Berlin, , Germany
Universitaetsklinikum Giessen, Oberarzt Neurologie
Giessen, , Germany
Medizinische Hochschule Hannover, Neurologische Klinik
Hanover, , Germany
Neurologische Abteilung
Henningsdorf, , Germany
Städtische Kliniken Osnabrück
Osnabrück, , Germany
Asklepios Klinik Schildautal
Seesen/Harz, , Germany
Fachbereich Neurologie und Klinische Neurophysiologie
Wiesbaden, , Germany
Hadassah Hebrew Uni Hospital, Department of Neurology
Jerusalem, , Israel
Sheba Medical Center, MS Center
Tel Litwinsky, , Israel
Universita di Genova, Clinica Neurologica
Genova, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):911-23. doi: 10.1056/NEJMoa044396.
Strijbis EM, Coerver E, Mostert J, van Kempen ZLE, Killestein J, Comtois J, Repovic P, Bowen JD, Cutter G, Koch M. Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 Oct;94(10):792-799. doi: 10.1136/jnnp-2022-330887. Epub 2023 May 12.
Related Links
Access external resources that provide additional context or updates about the study.
The web site of the National Multiple Sclerosis Society, an organization dedicated to providing information to individuals with MS, their families and healthcare providers.
MSActiveSource.com is a resource for news, information and disease management for all individuals touched by multiple sclerosis. This site is sponsored by Biogen.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-1802
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.